The B vitamins folic acid, vitamin B12 and B6 are essential for neuronal function, and severe deficiencies have been linked to increased risk of neurodevelopmental disorders, psychiatric disease and dementia. Polymorphisms of genes involved in B vitamin absorption, metabolism and function, such as methylene tetrahydrofolate reductase (MTHFR), cystathionine ␤ synthase (C␤S), transcobalamin 2 receptor (TCN2) and methionine synthase reductase (MTRR), have also been linked to increased incidence of psychiatric and cognitive disorders. However, the effects of these polymorphisms are often quite small and many studies failed to show any meaningful or consistent associations. This review discusses previous findings from clinical studies and highlights gaps in knowledge. Future studies assessing B vitamin-associated polymorphisms must take into account not just traditional demographics, but subjects' overall diet, relevant biomarkers of nutritional status and also analyze related genetic factors that may exacerbate behavioral effects or nutritional status.
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Genetic contribution of B vitamin polymorphisms in bipolar disorder and schizophrenia. 
Introduction
Vitamin B12, B6 and folic acid play important roles in the development, maintenance and function of the brain, and unsurprisingly, there has been intense activity on elucidating the role of B vitamin deficiency in psychiatric and neurologic diseases. However, the exact relationship between B vitamin status and risk of cognitive or behavioral disorders is unclear. For example, while epidemiological studies indicate B vitamin deficiency as a risk factor for cognition problems during normal aging, intervention studies have not produced robust effects (Tangney et al., 2009) . One possible reason for this lack of clarity may be due to polymorphisms which regulate B vitamin-associated biochemical pathways, either abrogating deficiency symptoms, or providing protection in the context of low intake (Haggarty, 2007) . This review will evaluate genes that regulate B vitamin function, which have also been linked to cognitive dysfunction.
Biochemistry and function of B12, B6, folic acid and related proteins
Vitamin B9 (folic acid or folate), B6 (pyridoxine and related vitamers) and B12 (also called cobalamin) play vital roles in methyl group donation for synthesis of proteins, lipids, nucleic acids, neurotransmitters, and hormones. In cells, vitamin B12 and folic acid are part of the methionine synthase (MS) complex that reduces homocysteine to methionine, which is then converted into S-adenosylmethionine (SAM), a crucial co-factor for 150+ methyltransferases including glycine n-methyltransferase (GNMT) in the one carbon pathway (Fig. 1) . After methyl group transfer, SAM becomes S-adenosylhomocysteine (SAH), which then becomes homocysteine, via the enzyme SAH hydrolase (SAHH), thus completing a cycle of methyl group transfer. Homocysteine also can be converted into glutathione, an important antioxidant, via series of intermediate steps requiring vitamin B6 as a cofactor and the enzyme cystathionine beta synthase (C␤S).
Folate facilitates methionine synthesis from homocysteine by acting as a cofactor for methylene tetrahydrofolate reductase (MTHFR) which converts 5,10-methylenetetrahydrofolate (CH 2 THF) to 5-methyltetrahydrofolate (CH 3 THF). CH 2 THF is generated from tetrahydrofolate by the enzyme serine methylhydroxytransferase (SHMT), which also uses B6 as a co-factor. Sufficient B12, B6 and folate therefore reduce levels of homocysteine, while deficiency of B vitamins can cause hyperhomocysteinemia, which is associated with increased risk of heart disease, cognitive problems and mood disorders (Almeida et al., 2008; Flickera et al., 2004) . Severe deficiencies of B12, folate or B6 can lead to macrocytic or pernicious anemia, syndromes characterized by fatigue, psychomotor, cognitive and mood deficits (Selhub et al., 2009) . Generally, vitamin B12 deficiency with sufficient folate allows for production of adequate SAM, while homocysteine levels remain high. Homocysteine has been implicated in amyloid buildup, DNA damage, mitochondrial dysfunction, nuclear disintegration, and apoptosis of neurons (Kruman et al., 2000) . Adequate supplies of SAM are crucial for maintenance of neurotransmitters and DNA synthesis (Frankenburg, 2007) .
Vitamin B12 also plays a role in conversion of methylmalonic acid-CoA into succinic acid-CoA for use in the tricarboxylic acid cycle. Specifically, the mitochondrial enzyme methylmalonyl Co-A mutase (MUT) requires B12 (in the prosthetic form adenosylcobalamin) as a co-factor. Very low levels of B12 or mutations in MUT may lead to methylmalonic acidemia, a disorder associated with severe brain damage, especially during development .
While the many intersecting pathways of the methyl donor system allow for some imbalance, too high or too low levels of B12, B6, folate or their co-factors may cause dysregulation of methyl donor activity, and also buildup of toxic intermediates such as homocysteine and methylmalonic acid (Fenech, 2010) . Moreover, imbalance of SAM/SAH causes further inhibition of methylation reactions crucial for cognitive function.
Clinical findings on B vitamin supplementation and cognitive or mood disorders
A full discussion of the many intervention studies investigating B vitamin modulation of behavior or cognition is beyond the scope of this review. To summarize the findings thus far: combinations of B vitamins, especially B6, B12 and folate, are more effective than single vitamin treatment and the likelihood of a significant effect appears dependent on baseline imbalance of plasma homocysteine and other methyl donor intermediates. However, with these studies there is a lack of consistency, especially for intervention studies in aged populations, in dosage used, length of intervention, experimental population, and assessments such as diet and lifestyle. Three trials of B12 and folate supplementation (using different doses and durations) in patients with dementia revealed no effect on cognitive function (Aisen et al., 2008; Vital Trial Collaborative Group, 2003 ). Yet another trial using mild cognitive impairment (MCI) patients (29 subjects with memory complaints), 2 months of folic acid increased attention and this effect was even stronger in those with low baseline plasma folate (Fioravanti et al., 1997) , while other trials using folic acid only supplementation produced no effects on cognition (Malouf and Grimley Evans, 2008) .
The evidence for B vitamin supplementation and alleviation of mood disorders is even weaker than that for cognitive decline, especially for B12 and B6. While small pilot studies with specially selected populations (patients with eating disorders, history of stroke or cardiovascular disease) have shown some effects of folic acid supplementation in monopolar or bipolar depression, systematic reviews indicate that the evidence is marginal (Sylvia et al., 2013; Taylor et al., 2004) .
In terms of physiological status, homocysteine levels are decreased more by concurrent folic acid, B6 and B12 supplementation (Vogel et al., 2009 ), which may partially explain why trials Fig. 1 . Schematic illustration of one-carbon metabolism pathways where vitamins B6, B12 and folic acid are cofactors in the pathway. Serine methyltransferase (SHMT) with co-factor pyridoxal phosphate (PLP) transfers a methyl group onto tetrahydrofolate (THF) creating CH2-THF; MTHFR via cofactor flavin adenine dinucleotide (FAD) creates CH3-THF. Methionine synthase reductase (MSR, also called MTRR) functionalizes methionine synthase (MS), which transfers a methyl group from homocysteine to produce methionine where B12 is an essential cofactor. Methionine is converted into S-adenosylmethionine (SAM) via MATI/II. Glycine methyltransferase (GNMT) converts SAM into S-adenosylhomocysteine (SAH). Note that GNMT is one of many methyltransferases and that SAH can be produced via other methyltransferases. Homocysteine is produced via S-adenosylhomocysteine hydrolase (SAHH), betaine-homocysteine S-methyltransferase (BHMT). Cystathionine ␤ synthase (C␤S) converts homocysteine to cystathionine. that supplement only one or the other often do not show positive results. Furthermore, baseline homocysteine levels in subjects appear to be linked to likelihood of cognitive deficit, thus indicating a subpopulation (within highly heterogeneous disease groups such as depression, schizophrenia and dementia) more likely to benefit from supplementation. For example, a recent study supplemented 187 mild cognitive impairment (MCI) patients (age 70 or above) with vitamin B12, B6 and folic acid for 24 months showed that slower brain atrophy due to treatment was correlated with baseline plasma homocysteine levels (Smith et al., 2010) .
In America where folate has been added to cereal grain products for decades, deficiency is now very low (<1% of the population) and B12 is the predominant B vitamin deficiency (Selhub and Paul, 2011) . Indeed, the 'masking' of B12 deficiency neurological symptoms by an abundance of folate also hinders diagnosis of hyperhomocysteinia, which contributes to higher rates of cognitive problems.
Role of genetics in B vitamin deficiencies
Genetic makeup may play an important role in which populations or subgroups will be more sensitive to B vitamin deficiency, and thus exhibit increased risk of mental disorders. Genetic differences may also explain the prevalence of hyperhomocysteinia and methylmalonic acidemia, since most Western diets provide adequate supplies of B12, B6 and folic acid. In fact, many cohort studies have shown that subjects' genotype predicts cognitive function more than plasma B vitamin levels (Wilson et al., 2010) . Genetic makeup has been shown to influence levels of serum metabolites in several genome wide association studies.
Aside from diet and genetics, plasma B vitamin levels are affected by many factors, such as age and environment, which may ameliorate or intensify neurological disease in carriers of susceptible genotypes. Not surprisingly, a major challenge for researchers is how to analyze genotype and interactions of genes that affect B vitamin bioavailability and function, while simultaneously integrating information on individual nutrient profiles and health or pathologies. Nonetheless, there is a growing view that B12, B6, folic acid and associated intermediates must be monitored simultaneously for appropriate nutrition recommendations in specific populations or individuals.
B vitamin transport genes and deficiencies
Vitamin B12 has a complex transport process through the body, beginning with binding to haptocorrin in the stomach, then to intrinsic factor (IF) in the intestines, moving (while bound to IF) into the bloodstream via cubilin receptors. Transcobalamin II (TCN2, or holotranscobalamin when bound) transports B12 to peripheral tissues. Studies in adults with neuropsychiatric disease have also suggested the presence of an active transport mechanism into the brain for vitamin B12, implicating the protein amnionless as a possible transporter (Luder et al., 2008) . Interestingly, B12 deficiency is frequently linked to poor absorption and metabolism rather than low consumption. Moreover, supplementation of B12 does not always resolve deficiency, pointing to inefficient or low levels of B12-related enzymes or transport proteins. For instance, in some individuals, B12 plasma levels may be normal but B12 intermediates, such as holotranscobalamin, may be reduced due to polymorphisms in the TCN2 gene. In addition, the TCN2 259R allele is associated with lower holotranscobalamin levels, especially in the cerebral spinal fluid of Alzheimer's patients (Zetterberg et al., 2003) . Hence, transport proteins such as IF, transcobalamin II, cubilin, and haptocorrin are attractive targets for assessing cognition-genotype relationships, since these genes are expressed in brain tissues, but to our knowledge only TCN2 has been significant associated to incidence of neuropsychiatric disorders. While some genetic diseases involving B12 metabolism have very severe effects on cognition, such as Immerlund-Grasbeck disorder, mutations in this gene pathway appear to be rare and thus beyond the scope of this review. Single nucleotide polymorphisms (SNPs) that are common (≥1% frequency) in the general population have weak effects on B12 levels. Only about 3% of Western populations have been reported to have plasma B12 deficiency. Free plasma B12, however, may not indicate true deficiency and B12 complexed with transholocobalamin or B12-associated intermediates (e.g., methylmalonic acid), may be more informative of bioavailability and functionality.
Folate found in food is often bound to glutamate or chains of glutamic acids. Folate hydrolase (also called N-acetyl-l-aspartyl-lglutamate (NAAG) peptidase) cleaves NAAG into N-acetyl aspartate (NAA), which also releases free folate from glutamate. Folate hydrolase plays a vital role in regulating not only brain glutamate, but also free folate availability. The 484C SNP of the folate hydrolase gene, FOLH1, have been implicated in negative symptom severity and treatment response in schizophrenia (Roffman et al., 2013) . Free folate is transported into cells via various transporters, including the reduced folate carrier, an organic anion antiporter that exchanges 5-methyltetrahydrofolate. Polymorphisms of its encoding gene, RFC-1, are implicated in homocysteinemia (Lucock and Yates, 2006) . Lastly, active folate is transported into the brain via the folate receptor alpha, which is abundantly expressed in the choroid plexus. Polymorphisms of the folate receptor alpha gene, FOLR1, have been reported in severe neurodevelopmental disorders and some brain cancers, and also may increase homocysteine levels, especially in conjunction with other folate-related genotypes (Grapp et al., 2012) . Genes related to B vitamin transport and metabolism, and their links to associated disorders are listed in Table 1, while Table 2 summarizes all the B vitamin genetic association studies discussed in this review.
Genetic contribution of B vitamin polymorphisms in neurodevelopment

B vitamin deficiencies and neurodevelopment
During pregnancy, large amounts of vitamin B12, B6 and folic acid are shunted to the fetus. Mothers deficient in these micronutrients become more depleted in order to sustain appropriate levels for brain development within the womb. However, infants can become B vitamin deficient in the first year of life, where longterm deficiencies can cause neurological symptoms such as apathy, tremor and fatigue (Finnell et al., 2008) . Apathy and fatigue symptoms may be due to folate's role in neurotransmitter production, while tremor symptoms appear to be related to the B12's role in myelination of neuronal axons, a prominent and rapid process which occurs during infancy. Some populations in Indian and Latin America become deficient due to lack of protein in their diet, and coupled with genotypes associated with poor B12 or folic acid uptake, infants can show brain atrophy and mental retardation (Black, 2008) .
B vitamin polymorphisms and intellectual ability in general populations
Only a few studies have analyzed B vitamin-related genes and their association with general neurodevelopment. For example, the incidence of neurodevelopmental disorders were higher in subjects homozygous for the hypomorphic version of the methionine synthase reductase (MTRR) A66G allele ) which has also been linked to high levels of homocysteine in children (Aléssio et al., 2007) . Another gene which has recently been reported to affect neurodevelopment is fucosyltransferase 2 (FUT2). The FUT2 protein is involved in production of gut antigens during infections, but which also affects plasma levels of B12 via modulation of cobalamin transporter expression in the gut (Hazra et al., 2008) . Bonilla et al. (2012) recently reported an association of maternal FUT2 rs492602 Homocysteine corr. to depression, comorbid cardiovascular disease and age of first episode but no effect of MTHFR Gaysina et al. (2008) 1222 British patients with MDD, 835 control subjects MTHFR C667T genotype; depression incidence No significant differences in genotype and depression Hong et al. (2009) T/T subjects → greater deficits on the VFT and WCST Roffman et al. (2011a,b) 18 schizophrenic patients (American) Bilateral ACC and the substantia nigra activation while performing an attention task MTHFR 667T allele carriers had less error-related activation than C/C patients Roffman et al. (2008b) 185 schizophrenic subjects (American)
COMT Val alleles and the MTHFR T alleles associated with more preservative errors in the WCST Tsutsumi et al. (2011) 407 Japanese schizophrenia cases and 384 controls DRD2, DRD4, GRIN2B, TPH1, MTHFR, and DTNBP1 No significant association of the genetic risk-index (7 polymorphisms) and disease Peerbooms et al. (2012) 98 patients with non-affective psychotic disorder and 118 controls (Dutch) (Black, 2008) . Lack of B12 to the developing brain may have lifelong effects in what appear to be intellectually normal children. SNPs in several genes related to B12 metabolism, i.e., methionine synthase (MTR), methylene tetrahydrofolate reductase (MTHFR) and cystathionine ␤ synthase (CˇS) and their association with cognitive ability as measured by IQ tests were also studied. The CˇS 844ins68 allele, which decreases efficiency of the enzyme, was significantly under-represented in children with high IQ (Barbaux et al., 2000) . Although brain C␤S expression is only 20% of that of expression in the periphery, this finding suggests that metabolism of homocysteine via C␤S may be an important factor for optimal brain development.
The MTHFR C677T polymorphism has attracted great interest since the T variant causes a thermolabile form of MTHFR, which requires much higher levels of folate than the C variant to stabilize the binding of flavin-adenosine-dinucleotide (FAD). Thus carriers of the T allele are more susceptible to folic acid deficiency, as well as developmental syndromes and later psychiatric illness. MTHFR has been analyzed or discussed in over 2500 publications (PubMed) in many diverse phenotypes and conditions. For example, one recent study investigated the MTHFR C677T polymorphism by measuring cognition in 235 Mexican toddlers (via the Bayley's Scale) and associating scores with either nutritional status or genotype. Deficiency of vitamin B12 was negatively associated with mental development while low dietary intake of folate (<400 mg/day) reduced Bailey's Scale scores in children of TT genotype carriers only (del Río Garcia et al., 2009) .
With regard to more intellectually disabled children, no association of the MTHFR genotype or degree of impairment in a report that examined 100 severely mentally retarded children (i.e., without trisomies) compared to 743 normal controls (Shaw et al., 2007) . In a follow up study, 226 children with idiopathic intellectual disability (IID) were tested, along with their nuclear families, for associations to B12 and folate cycle gene polymorphisms (Dutta et al., 2011) . Specifically, significant differences in genotype frequencies were observed for the polymorphisms: MTR A2756G, MTRR A66G, and DHFR rs70991108 in IID subjects as compared to controls.
B vitamin polymorphisms and Down's syndrome
Due to MTHFR's role in methyl donation, several studies have examined the relationships between the C677T polymorphism and risk of having a Down's syndrome (DS) child. They have shown that having one of the 'risk' alleles (C677T or A1298C MTHFR polymorphic variants) increases one's chance of having a Down's syndrome baby while two risk alleles further increases incidence (Martínez-Frías, 2008) . Another study using a separate set of polymorphisms: CˇS 844ins68, MTR A2756G, reduced folate carrier (RFC-1) G80A and transcobalamin (TCN) G776C in 114 mothers of Down's children and 110 matched controls found no correlations, indicating that offspring genotype may be more important than maternal genotype at these alleles (Fintelman-Rodrigues et al., 2009) . A study examining the interactions of B12-related alleles found that the MTR AG genotype was a significant risk factor for having a Down's syndrome child or being a Down's syndrome case . In addition, carriers of both the MTR A2756G and the MTRR A66G genotypes had even higher risk of having a DS child. Additionally, in a follow up study researchers found that plasma homocysteine, the MTHFR 677T allele and transcobalamin (TCN) 776G allele were negatively associated with IQ in Down's syndrome patients (Guéant et al., 2005) .
B vitamin polymorphisms and autism
Folic acid supplementation has been linked to lower incidence of autism in a cohort of over 85,000 children (Surén et al., 2013) . B vitamin-related genes have also been analyzed in subjects with autism or autistic spectrum behaviors. In autistic disorder and pervasive development disorder (PDD) groups, plasma levels of methionine, cysteine and total blood glutathione were found to be reduced, while plasma homocysteine, vitamin B12, and folate were in the normal range (Paş ca et al., 2009 ). The results of the MTHFR gene analysis showed a trend of the 677T allele as slightly more prevalent in AD patients. Another group, using data from the Autism Genetic Resource Exchange (AGRE), analyzed symptomology as defined by the Autism Diagnostic Interview-Revised (ADI-R) and found that the following four behaviors were positively associated with the MTHFR T allele: poor direct gaze, current complex body movements, a history of self-injurious behavior, and current overactivity (Goin-Kochel et al., 2009 ).
In conclusion, the above findings point to a meaningful role of B vitamin-related genes in select neurodevelopmental syndromes. Replicating these associations will be challenging due to the low frequency of the risk alleles of MTHFR, MTR, MTRR, and DHFR in some populations (Martínez-Frías, 2008) . For example, MTHFR C677T and MTRR A66G polymorphisms are associated with a greater risk of having a child with DS in North America, Ireland, and The Netherlands, but not in Sicily or France , possibly due to the differential incidence of these alleles in the general populations of these regions. Interestingly, a recent pilot intervention study of leucovorin (folinic acid) in autistic children displaying folate receptor auto-antibodies improved several behavior indices (Frye et al., 2013) . These results support the notion that bioactive folate is deficient in some cases of autism, and may possibly be influenced by genes involved in one carbon metabolism. Future studies require multivariate analysis of environmental, physiological, nutritional and genetic data of parents and offspring to generate 'risk intersections' of these factors.
Genetic contribution of B vitamin polymorphisms in depression
B vitamin bioavailability and depression
Low B vitamin status has long been linked to depressive behavior, especially subjects with lethargic, apathetic symptomology (Semmes, 2005) . S-adenosyl methionine (SAM) has been repeatedly shown as just as effective as many currently prescribed antidepressants (Coppen and Bolander-Gouaille, 2005) . How SAM can function as a neuroactive agent is not clear since a SAM cell membrane transporter has not been identified. SAM could be transported across cellular membranes by one of the many members of the organic ion and ATP cassette transporter families or via analogs of mitochondrial SAM transporters, but this has not been proven in the literature (http://omim.org/entry/611037). More bioavailable forms of folate and B12, 5-methyltetrahydrofolate (also called methylfolate) and methylcobalamin, have also been touted as depression therapies (Coppen and Bolander-Gouaille, 2005) .
General depressive disorders
Although B vitamin deficiency is linked to depression incidence, it has proved difficult to show a significant association of B vitamin polymorphisms. In fact, even highly publicized 'risk' alleles such as the 'short' version of serotonin transporter promoter (5-HTTLPR) has not been conclusively linked to depression incidence, probably because of the heterogeneous nature of the disease. Some strong, though still debated, evidence has been generated for association of the MTHFR C677T polymorphism with depression.
While GWAS studies have failed to significantly link any polymorphisms to depression, two meta-analyses of 20 and 26 studies respectively showed a significant effect from the MTHFR C677T polymorphism on incidence of depression (López-León et al., 2008; Wu et al., 2013) . However, there may be ethnicity consideration that add complexity to these findings, since another meta-analysis assessed the influence of the MTHFR C677T polymorphism in 5 studies and concluded that the dominant allele (T) had an association with depression in Asian but not Caucasian populations (Zintzaras, 2006) . In contrast a large study of 3478 European women found a strong association between the MTHFR C677T genotype and three indicators of depression (history of depression, antidepressant use, or the EuroQoL mood questionnaire). In the same article, a meta-analysis of eight studies also indicated a strong link of the T allele to depression risk (Lewis et al., 2006) .
In order to clarify the association of MTHFR genotype in depression several groups have used symptom severity or treatment response as co-variates. A recent study involving 402 depressed subjects and 600 controls (Han Chinese ethnicity), found a positive association between high Hamilton Rating Scale for Depression (HAMD)-17 scores and TT or CT genotypes . Another study that examined 90 subjects with depression secondary to traumatic brain injury found that those with MTHFR TT genotypes predicted greater treatment response with 50 mg citalopram (Lanctt et al., 2010) . However, many individual studies have failed to show a MTHFR C677T association with depression incidence. For instance, Almeida and colleagues reported that for 580 depressed patients the Beck Depression Inventory (BDI) score of TT genotype subjects was unchanged compared to other MTHFR genotypes (Almeida et al., 2005) , although plasma homocysteine strongly correlated with BDI scores, as well as B12 and folate levels. Two other studies using large cohorts of depressed patients and controls found no association of the MTHFR C677T polymorphism to disease incidence (Gaysina et al., 2008; Lizer et al., 2011) . However, these studies did not use co-variate data such as symptom severity or progression to identify more complex interactions of MTHFR alleles and mood. One approach successfully used to discern such interactions demonstrated that childhood trauma and MTHFR TT genotype predicted depression risk (Lok et al., 2013) .
Geriatric depression
Studies focusing on depressed elderly subjects have found significant associations with plasma B12 levels, possibly due to a higher rate of age-related gastritis which decreases intrinsic factor (IF) expression causing reduced B12 uptake (Tiemeier et al., 2002) . Age-induced B12 deficiencies make it more difficult to demonstrate genetic linkage to depression in older subjects. In a study of 116 patients with geriatric depression plasma homocysteine was significantly higher than compared to healthy controls, and there was a correlation with the age of first episode and comorbid cardiovascular disease with homocysteine levels (Yuan et al., 2008) . However, there were no significant differences in the MTHFR C677T polymorphism genotypes and alleles between the patients and the healthy controls. This finding was supported by a later study performed with elderly Chinese depressed patients and age matched controls, where the 677T allele was not more frequent in depressed subjects or related to cognition or gray matter hyperintensity volume (Hong et al., 2009) .
Some studies have found some positive genetic relationships to geriatric depression by using novel biomarkers or associated health conditions as covariates. One of the earliest studies on the association of MTHFR and geriatric depression found higher incidence of the T allele subjects with vascular risk factors (Hickie et al., 2001 ).
Another geriatric depression study showed that the C677T MTHFR T allele was associated with higher scores in the Hamilton Depression Index (HADS), while plasma thiol dipeptide Cys-Gly, which is a product of folate and glutathione metabolism, was negatively associated to the T allele (Naumovski et al., 2010) . Lastly in 538 elderly east Asian subjects the MTHFR TT genotype was associated with general somatic morbidity and incidence of depression (Kim et al., 2009 ).
Pregnancy-related depression
Folic acid supplementation for pregnant women is now a wellestablished preventative measure against neural tube defects, but more recently epidemiological data on B vitamin intake and postpartum depression has emerged, with some interactions toward genotypes (Black, 2008; Lewis et al., 2012; Selhub and Paul, 2011) . Folic acid supplementation during the last two trimesters had no effect on development of depression 0-8 months after delivery, yet did have a slight effect 21 months postpartum, and this effect was intensified in women with the MTHFR C677T TT genotype . The MTHFR C677T allele also was associated with greater depressed mood during pregnancy and poor mood predicted less methylation in both maternal and neonatal 5-HTTLPR promoter regions (which regulates expression of the serotonin transporter) (Devlin et al., 2010) . Surprisingly, few depression association studies have investigated the interaction of polymorphisms related to monoamine function since B vitamins are involved in monoamine metabolism.
Few studies have assessed depression linkage to polymorphisms in other B vitamin interacting genes. Ye et al. studied polymorphisms in folate polyglutamate synthase (FPGS), ␥-glutamyl hydrolase (GGH), methionine synthase (MTR), proton-coupled folate transporter (PCFT), and reduced folate carrier 1 (RFC1) genes in 976 Puerto Rican adults, aged 45-75 years, and none of the variants were related to depression (Ye et al., 2011) . The folate hydrolase (FOLH1) C1561T polymorphism was significantly associated with lower CES-D score and TT and TC genotypes were less likely to report depressive symptoms. A study of 83 Polish women with post-partum depression and 89 controls investigated the association of MTHFR, MTR, and MTHFD1 polymorphisms according to the severity of depression. After stratification of symptoms, the MTR GG genotype was shown increase the risk of depression 5-fold, while MTHFR and MTHFD1 genotypes had no influence (Słopien et al., 2008) .
Genetic contribution of B vitamin polymorphisms in bipolar disorder and schizophrenia
Schizophrenia incidence and MTHFR polymorphisms
Genetic analysis of B vitamin-related genes has been more prevalent in studies schizophrenia or bipolar disease, where there is estimated heritability of 80%, as opposed to unipolar depression, where heritability is estimated to be around 40% (Stringer et al., 2011) . While schizophrenia and bipolar depression are less heterogeneous diseases compared to unipolar depression, the more robust heritability results may be due to the higher severity of cognitive and behavioral problems in the former diseases. Better phenotyping makes it easier to find associations and the best example is MTHFR C677T. In one recent meta-analysis of MTHFR C677T (n = 29,502) researchers found a significant associations in schizophrenic and bipolar but not unipolar depressive patients. However, unipolar depression association studies have not been widely performed (Peerbooms et al., 2011) .
While a majority of single cohort studies have found positive polymorphism associations mostly with MTHFR alleles, meta-analyses report contradictory findings, which may be a consequence of inclusion criteria for subjects and a greater range of ethnicities in recent studies. No significant association between either allele of the MTHFR C677T polymorphism and the risk of developing bipolar disorder, depression or schizophrenia was found in a meta-analysis of 10 studies (Zintzaras, 2006) . In contrast, a more recent meta-analysis investigated the relative associations of 20 different polymorphisms previously linked to schizophrenia and found that MTHFR C677T was one of the 6 that showed a significant association . In this same meta-analysis, which used a database of over 1000 genetic association studies ('SzGene'), other well-known genes such as apolipoprotein E (APOE), dopamine 2 receptor (D2DR) and catechol-O-methyltransferase (COMT) were reported to have no effect on incidence of schizophrenia . Lastly, the authors remarked that these findings supported an epigenetic role in these diseases.
The association of MTHFR C677T and schizophrenia is still controversial. In a meta-analysis of studies using east Asian populations, the population attributable risk was only marginally significant for C677T and schizophrenia, as well as bipolar depression (i.e., increased risk for T allele carriers) (Shi et al., 2008) . However, in a genome wide association study (GWAS) of 696 Japanese schizophrenic patients compared to 774 controls, imputational analysis showed no relationship of MTHFR genes (4 SNPs in total) to risk of developing schizophrenia (Yoshimi et al., 2010) . Lastly, a 'risk index' model was used to study whether 384 schizophrenic patients exhibited a higher incidence of polymorphisms previously associated with schizoid disorders by adding together the number of genetic risk factors (methylenetetrahydrofolate reductase; MTHFR, dopamine 2 receptor; DRD2, dopamine 4 receptor; DRD4, glutamate receptor ionotropic NMDA subunit 2b; GRIN2B, tryptophan hydroxyolase; TPH1, and dystrobrevin binding protein 1; DTNBP1) (Tsutsumi et al., 2011) . However, the 'risk index' was similar between patients and controls, belying the notion that schizophrenia incidence can be predicted by a limited collection of risk genes in the absence of behavioral or biochemical co-variates.
MTHFR polymorphisms, biomarkers and behavioral phenotypes
More in-depth analyses of schizophrenia risk and MTHFR have examined familial genotypes, nutritional status, age of onset and season of birth as co-variates. The C677T polymorphism significantly affected age at onset of schizophrenia, with lower age of onset coinciding with increased T-allele frequency in 820 Scandinavian schizophrenic patients (Vares et al., 2010) . In the same study, the MTHFR T allele was associated with earlier age at onset than siblings homozygous for the C allele in group of high-risk families of Chinese descent (two or more affected siblings, n = 221). Lastly, a study examining season of birth and incidence of schizophrenia found no association of MTHFR C677T genotypes and schizophrenia risk in Dutch subjects (Muntjewerff et al., 2011) .
Inclusion of brain imaging and challenging cognition tasks have also been used to increase genetic association robustness. Rothman and associates have extensively analyzed the relationship between MTHFR, brain activation and cognition in schizophrenic patients. In an initial study, this team showed that the MTHFR 677T allele was associated with worse executive function using a Verbal Fluency Test and a Wisconsin Card Sort Test (WCST) (Roffman et al., 2007) . Subsequent studies from this group used fMRI to analyze activation of two dopaminergic regions, the bilateral anterior cingulate, and the substantia nigra in 18 schizophrenic patients performing attention task. They found that MTHFR 677T allele carriers had less error-related activation than C/C patients (Roffman et al., 2011a) .
The MTHFR polymorphism C677T also appears to play a role in reducing positive symptoms via antipsychotic treatment. Six polymorphisms were investigated for association to antipsychotic efficacy in 329 Dutch patients using the Clinical Global Impression-Improvement (CGI-I) scale to assess behavioral changes. Those individuals with the MTHFR T allele showed more improvement with atypical antipsychotics such as olanzapine, which may be linked to the previous associations of this allele to behavioral disturbances (Vehof et al., 2012) . However, better treatment response may also couple with other physiological changes, since a separate study revealed that schizophrenic subjects with the MTHFR T allele had higher risk of metabolic syndrome after antipsychotic treatment . Interestingly, a study with 200 schizophrenia patients showed a positive relationship of folic acid status, MTHFR 677T allele, and reduced negative symptoms (Roffman et al., 2008c) . This 3-way relationship was supported by results in 32 schizophrenia patients who received either folic acid (2 mg/d) or placebo, where a reduction in negative symptoms was noted in MTHFR T allele carriers whose folate also rose from treatment (Hill et al., 2011) .
Epistatic contribution of COMT to MTHFR
COMT, the enzyme which breaks down dopamine, has long been implicated in schizophrenia and is also a major methyl donor enzyme. Carriers of both COMT Val alleles and the MTHFR T alleles showed more preservative errors in the WCST (Roffman et al., 2008b) . In a supporting study with 79 schizophrenia patients and 80 controls, the T allele was associated with decreased prefrontal working memory activation in dopaminergic brain regions, adding credence that the MTHFR T allele was associated with decreased dopamine function (Roffman et al., 2008a) . Interestingly, the MTHFR TT and COMT Val/Val genotypes were associated with reduced prefrontal activation in schizophrenics, and with CC and Met/Met genotypes in controls. In subjects with MTHFR T and COMT Val alleles, prefrontal cortex dopamine levels were correlated with poor information processing and working memory (Roffman et al., 2008a) . COMT Val/Met and MTHFR C677T polymorphisms are also associated with reactivity due to daily life stress. Anxiety was significantly increased in 98 schizophrenics homozygous for COMT Met and MTHFR T alleles, while no effects of genes were seen in 100 non-schizophrenic controls (Peerbooms et al., 2012) .
A recent review addressed the COMT Val/Met allele polymorphism and concluded that optimal functioning of dopamine may have a U-shaped curve where too little or too much causes dysfunction. MTHFR may exacerbate a COMT-mediated imbalance of dopaminergic signaling (Witte and Flöel, 2012) . The above family of association studies point to a more mechanistic exploration of MTHFR C677T cognitive roles by revealing epistatic interactions which may be modifiable via carefully controlled supplementation. Analysing COMT polymorphisms in combination with other B vitamin pathways may be efficacious since the methyl transfer function of this enzyme is so tightly linked to B vitamin sufficiency. Other genes shown to have epistatic relationships with COMT are DISC1, RGS4 and BDNF (Nicodemus et al., 2007; Witte and Flöel, 2012) , where cognitive ability is enhanced or impaired via particular gene combinations.
Cystathionine beta-synthase
Compared to the extensive analyses of MTHFR interactions with schizophrenia, very few studies have examined other Bvitamin associated genes. The 844ins68 polymorphism of the cystathionine beta-synthase (CˇS) was associated to increased risk of schizophrenia and also to changes in attention and auditory evoked potentials (Golimbet et al., 2009 (Golimbet et al., , 2010 . A mouse model of CˇS overexpression was shown to have improved hippocampal signaling versus wild-type mice, while mice deficient in C␤S display higher SAHH and Dyrk1A, a kinase involved in methylation with putative roles in Down's syndrome cognitive dysfunction (Becker and Sippl, 2011) . Lastly, Roffman et al. recently published a study showing that MTR 2756A and FOLH1 484C contributed more potently to negative symptom severity than MTFHR C677T genotype (Roffman et al., 2011b) .
Cognitive decline/dementia
Unlike several developmental and psychiatric disorders, no meta-analysis has been reported for MTHFR or any other B vitaminrelated SNPs for cognitive decline. While the contribution of B vitamins to brain aging has been demonstrated frequently, association of polymorphisms in other B vitamin genes with cognitive decline have not been found, perhaps because of confounding of age-related decreases in B vitamin absorption and metabolism. However, in cognitive decline studies there has also been more attention to not just MTHFR polymorphisms but also other genes associated with Alzheimer's incidence, such as APOE.
MTHFR and cognitive decline
Recent reports describe the use of several B vitamin biomarkers and genes to identify possible synergies of the MTHFR polymorphism with more extensive physiological data. For instance, Religa and colleagues found that only Alzheimer's patients with high baseline homocysteine and low plasma folate had higher incidence of the MTHFR TT genotype (Religa et al., 2003) . This same study also indicated that APOE-epsilon4 alleles were independently distributed in such patients (Religa et al., 2003) with no apparent epistatic relation to MTHFR. A found positive association of MTHFR TT genotype and ability on a psychomotor task in 818 elderly subjects but not other types of cognition (Durga et al., 2006) . In contrast Flickera et al. examined APOE and MTHFR C677T status, and plasma amyloid, APP, APOE and homocysteine in 299 elderly men, and found no association with MTHFR for any variable. In contrast, APOE epsilon4 strongly predicted cognition and depression (Flickera et al., 2004) . B12 status was positively associated with cognition as assessed by the MMSE performance the association was stronger in those with APOE epsilon 4 genotype (Feng et al., 2009) . Conversely, Abello showed that Italian AD patients had higher than average homocysteine levels which were potentiated by MTHFR T and APOE epsilon 4 status . In a study conducted in China, 356 elderly males with no major neurological disorders were assessed by the Cognitive Abilities Screening Instruments (CASI) and the Wechsler Digit Span Task tests and tested for MTHFR C677T genotype; TT and CC homozygotes did worse on the CASI compared to C/T carriers, suggesting that a median level of MTHFR activity may be most beneficial for cognition (Tsai et al., 2011) . High homocysteine and MTHFR 677T were associated with intima-media thickness, a physiology indicative of microvascular damage (Gorgone et al., 2009) .
Two longitudinal studies showed nominal association of MTHFR TT genotype status with measures of decline. Positive correlations of the TT genotype were associated with lower scores on the Digit Symbol Substitution Test, Trails B test and with annual decline on the Mini-Mental State Examination (MMSE) (Elkins et al., 2007) . Baseline homocysteine predicted risk of dementia over a 10 year period in 4337 healthy aged men . However, the study was underpowered for conclusive understanding of MTHFR polymorphisms on development of dementia.
On the whole it appears that effects of MTHFR on age-related cognition are subtle and inconsistent.
TCN2, MTR, MTHFD1, GCPII
Garrod and colleagues (2008) found a relationship of high homocysteine and low holotranscobalamin to poor cognitive function. TCN2 776 GG polymorphisms were associated with low plasma holotranscobalamin and high homocysteine in elderly Latino patients. Unfortunately, the effect of genotypes on cognition was not directly tested (Garrod et al., 2010 (Garrod et al., , 2008 . The T776C polymorphism may affect the folding of the transcobalamin protein, possibly reducing affinity for B12, although this proposal has not been conclusively tested (Riedel et al., 2011) . TCN2 status also affects homocysteine levels but it has not been analyzed as extensively as MTHFR.
The methionine reductase (MTR) A2756G polymorphism was analyzed in 152 patients with Alzheimer's disease and 136 controls. Homozygosity for the A allele was associated with greater severity of dementia, which increased when subjects were also APOE4 or IL-6 CC carriers . This potential genegene interaction may be due to homocysteine's neurotoxicity via oxidative stress and amyloid beta generation. APOE4 has been shown to increase amyloid beta levels by reducing brain clearance compared to epsilon 2 and 3 (Brown et al., 2011) . Other studies have shown no effects of B12 related polymorphisms such as MTR A2756G genotypes, thymidylate synthase (TS) 2R→3R and serine hydroxymethyltransferase (SHMT1) 1420C→T on cognition in elderly subjects (Bathum et al., 2007; Schiepers et al., 2011) .
The glutamate carboxypeptidase (GCPII) C1561T polymorphism appears to increase plasma folate and decrease homocysteine, as well as scores in the Symbol Digit Modalities Test (SDMT) in aged Norwegians . However, no effects of GCPII or FOLH1 genotypes were found for indices of depression or alcohol use in this population. Finally, a study in Chinese Alzheimer's patients found a very weak association of the MTHFD1 G1958A A allele for early onset AD, but found no association of the CˇS 844ins68 polymorphism (Bi et al., 2010) .
Discussion
While many epidemiological studies have shown that B vitamin deficiency is associated with various psychiatric and cognitive issues, B vitamin supplementation has had little effect on its own. Since 'vulnerability' genotypes such as MTHFR 677TT have low frequencies in many populations and its effects are subtle, the numbers of subjects needed for a B vitamin intervention study, with sufficient groups of homozygotes, is unfeasible. Yet observational studies using cohorts are not appropriate to test whether psychiatric and cognition issues are reversible or even caused by changes in B vitamin intake. Although analyses of variants in several B vitamin metabolic pathways seem promising in genetic association studies, the contribution of a single gene or small subset of genes is not likely to show reproducible effects, due to different genetic populations or different diets. More consistent intervention study outcomes were observed in subjects with baseline homocysteinuria or other markers of imbalanced methyl donor status, where genotype status contributes to an imbalance and thus is amenable to correcting levels of nutrients. However, as stated earlier, selection or stratification of subjects based on self-report questionnaires or even plasma B vitamins may not indicate levels of active forms such as methylcobalamin or methylenetetrahydrofolate. Thus future studies would be well served by selection of subjects with imbalances in active or downstream components of the methyl donor pathways, like SAM/SAH.
Even with some successes in showing genotype contributions, the value of assessing genetic analysis of behavioral diseases can be questioned even for those conditions with strong hereditary contributions. In fact, most available studies show negligible effects of single genes such as MTHFR, MTR and CˇS polymorphisms. While the MTHFR C677T polymorphism may mediate significant effects on populations of schizophrenics, it contributes 1-3% to the incidence and 1-3% to the risk of severity. General practitioners, clinical trial researchers, or health policy analysts would not likely consider genetic testing or treatment for most psychiatric disease because of the limited evidence.
A more promising experimental design would be based on systems biology approaches to map the synergies of multiple genotypes in subjects, combined with improved assessments of nutritional intakes, more exhaustive physiological analyses, and standardized psychiatric or cognitive testing. Since one carbon metabolism is involved in many basic processes, the systems approach might include assessing 'omics' or customized panels relating to nutritional pathways. For instance epigenetic modifications of many neurodevelopmental genes have been shown to be attenuated by folic acid and B12 deficiencies (Schaevitz and Berger-Sweeney, 2012) . Similarly, MTRR or MTHFR genotypes are also associated with methylation status of genes involved in neurodevelopment such as IGFBP3 and IGF2 (McKay et al., 2012) .
Methyl donor deficiency may strongly impact epigenetic remodeling during key periods of development, and these epigenetic changes are likely intensifying the genetic influence of B vitamin genotypes. Indeed, Burghardt and associates reported that female schizophrenics with MTHFR 677TT genotypes had the lowest levels of DNA methylation in blood cells, indicating a possible role of epigenetic contribution to mental illness as well as comorbidities such as metabolic syndrome (Burghardt et al., 2012) . 'Hypomethylating' B vitamin genotypes may be contributing to the notable diversity of neurological and psychiatric diseases linked to one carbon pathway polymorphisms. Depending on complex interactions of environment, diet and genetics, deficiencies in methylation capacity may give rise to differential changes in sets of proteins involved in schizophrenia, depression or dementia pathology. However, it must be noted that DNA methylation status of brain versus peripheral tissue is not consistent, and thus it will be important to validate mechanisms of nutritional and epigenetic interactions using animal models. These models could also incorporate analysis of other epigenetic mechanisms such as microRNA expression and histone deacetylation (Roth and Sweatt, 2011; Stone et al., 2011) .
Translating animal model results to humans may not require large numbers of participants using systems analyses and n-of-1 experimental approaches (Lillie et al., 2011) . These types of studies require longitudinal analyses with more exhaustive phenotyping of the participant, but also better analysis of metadata: socioeconomic, psychological history, and other lifestyle measures. The combination of 'phenotyping' data with new strategies such as middle out analysis methods may provide a means to better understand complex phenotypes (Majumder and Mukherjee, 2011; de Graaf et al., 2009 ). The use of middle out methods can ultimately focus analysis on an expanded subsystem of genes contributing to the phenotype studied. For instance, SAM-dependent methyltransferases are a large family of enzymes that are unconnected to each other except for the need of adequate SAMe supplies to function. COMT is the best known of this genes family and its variants have been shown to be associated with psychiatric diseases. Polymorphisms in other SAM-dependent enzymatic genes would be expected to have much more severe effects in individuals with B12 or folic acid-related polymorphisms. Besides methyltransferases, SAM transporters have also not been well-studied for associations to mental health, thus further research is needed to identify other genes which affect SAM bioavailability as well as metabolism, and apply these sets of genes to clinical outcomes. Although few trials have applied focused genotyping panels based on particular pathways or families of enzymes, with the pace of technological advances in sequencing, even small n studies may benefits from these practices.
One of the difficulties of measuring a micronutrient deficiency's effect on behavior is the lack of consistent methods for assessing an individual's needs and responses, since optimal nutrient status will be different depending on genotype. Genes involved in transport, such as transcobalamin 2 (TCN2) may contribute to less efficient uptake of vitamin B12, yet standard measures of B12 in plasma may not show this deficit, thereby overlooking 'sufficient' psychiatric patients who may benefit from nutritional therapy. A recent study demonstrated that serum holoTC, but not plasma vitamin B12, MMA, or tHcy, varied according to TCN2 67A→G genotype (Riedel et al., 2011) . The contribution of this gene to deficiency would not be found by focusing on free vitamin B12 levels alone. Another interesting development in nutritional research is the development of computational models that may shed more light on how fluxes of B vitamin bioavailability proteins will alter propensity for mental illness risk.
In conclusion, diverse clinical studies have revealed weak and in some cases inconsistent associations of cognition, mood and neurodevelopment disorders to genes involved in B vitamin metabolism. Use of new experimental models and designs, more extensive phenotyping, and more detailed understanding of an individual's exposures to stress, diet, and lifestyle will likely improve the consistency and reliability of genotype-nutrient-behavior interaction data.
